Rep. Maria Elvira Salazar (R-FL) Sells Biogen (BIIB) Stock
Rep. Maria Elvira Salazar, a Republican from Florida, sold shares of Biogen Inc. valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Maria Elvira Salazar (R-FL) sold between $1,001 and $15,000 of Biogen Inc. ($BIIB) stock on September 24, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 7, 2026.
Since the trade, $BIIB is down 1.6% after 1 week and up 2.8% to date (from the $226.36 close on Sep 24, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Maria Elvira Salazar (R)
- Status:
- Member — House
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 7, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Biogen Inc. ($BIIB) | Sell | Sep 24, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
BIIB
Biogen Inc.
Key Points
- Rep. Maria Elvira Salazar sold shares of Biogen Inc. valued between $1,001 and $15,000 on September 24, 2026.
- Biogen shares recently traded around $233.54, which is above its 50-day moving average by 6.6%.
- The company's next earnings report is scheduled for October 28, 2026.
Get $BIIB trade alerts by text
We text you when insiders, Congress or big funds trade $BIIB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures
Rep. Maria Elvira Salazar, a Republican from Florida's 27th district, sold shares of Biogen Inc. (NasdaqGS: BIIB) valued between $1,001 and $15,000 on September 24, 2026. This transaction was reported on October 7, 2026, as part of her periodic transaction report under the STOCK Act.
Maria Elvira Salazar vs. the S&P 500
Hypothetical returns from Maria Elvira Salazar's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Biogen
Several institutional investors have adjusted their positions in Biogen. FMR, LLC increased its holdings by 5,409,844 shares, bringing its total to 18,217,239 shares worth about $4.24 billion. Blackrock Inc. added 11,182 shares, ending with 15,985,736 shares valued at approximately $3.72 billion. Primecap Management Company grew its stake by 396,980 shares, totaling 15,154,606 shares worth about $3.53 billion. Vanguard Capital Management LLC and State Street Corporation also made changes, increasing their shares to 9,651,117 and 7,344,327 respectively, valued at around $2.25 billion and $1.71 billion.
Biogen Inc. Stock Down 0.8%
Biogen's stock is currently trading around $233.54 as of October 16, 2026, which is above its 50-day moving average by 6.6% and its 200-day average by 18.2%. However, the stock is about 3.1% below its 52-week high of $240.99. The average target price from analysts is $243.98, indicating that the stock is trading below this target by 4.3%.
Recent Earnings
Biogen reported trailing twelve-month revenue of approximately $10.03 billion, with a net margin of 8.3% and a return on equity of 4.6%. The company has shown a year-over-year revenue growth of 3.4%. Its next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
In recent months, several insiders have traded Biogen shares. On February 9, 2026, Officer Priya Singhal sold 2,660 shares for a total value of $531,548 at an average price of $199.83. Another officer, Nicole Murphy, bought 3 shares on February 12, 2026, valued at $585. Director Lloyd B. Minor sold 1,186 shares on August 4, 2026, valued at $239,750.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Biogen. On August 4, 2026, Mizuho maintained an Outperform rating with a target of $241. On August 13, 2026, Wolfe Research upgraded the stock to Outperform with a target of $300. RBC Capital also maintained an Outperform rating with a target of $260 on August 25, 2026. Piper Sandler reiterated its Overweight rating, raising its target to $245 on September 3, 2026, while HSBC maintained a Reduce rating with a target of $175 on September 10, 2026.
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the healthcare sector, focusing on neurological diseases. Headquartered in Cambridge, MA, the company employs around 7,500 people. Biogen's recent stock activity and analyst ratings suggest ongoing interest in its performance and potential growth.
Bottom Line
Investors and analysts will be watching Biogen closely, especially with its next earnings report coming up on October 28, 2026. Maria Elvira Salazar's recent sale adds to the ongoing discussions about insider trading activity within the company.
Related Filing Alerts
Source: Maria Elvira Salazar's STOCK Act disclosure on $BIIB (Sep 24, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts